Morgan Stanley analyst Michael Ulz maintained a Hold rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...

The global artificial intelligence in clinical trials market, valued at US$1.20 billion in 2023, is forecasted to grow at a ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...

Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...

Trial underscores IROS's commitment to developing innovative therapies for unmet medical needs <li /> The study's success ...

Imagine having a digital carbon copy of yourself that physicians could use to predict long-term risks for disease, assess how your body may respond to treatment, and simulate surgeries in advance. A ...

To start the year right, Fred Hutch scientists, providers and a patient advocate share tips to help readers keep up with the deluge of health and science information.

Cannabis has long been a controversial substance, particularly within the world of professional sports, where its use has ...

The gene neuropilin2 regulates inhibitory neuron migration and excitatory neuron connections, essential for balanced brain activity.

Discover what DeSci is, how it works and the transformative effects of decentralized science on funding, research and ...

Tran Le was an engineering student at Stanford University when she tried to enroll in a clinical trial for her chronic ...